Clinical Trial Update: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inhaled GM-CSF to improve host defense and pulmonary barrier restoration in acute respiratory distress syndrome (ARDS) has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• GM-CSF inhalation (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: University of Giessen | Conditions: ARDS | Phase 2 | Status: COMPLETED